ArticleCirculation. Heart failure2021
PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.
Abstract read
In one paragraph
Article in Circulation. Heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Pathway in High-Risk Lymphocytic Acute Myocarditis.JACC. Advances · 2026Article
- Expression of PD-1/PD-L1 pathway molecules in human cardiac allograft according to acute cellular rejection status: insights from a Korean Heart Transplant Cohort.Journal of pathology and translational medicine · 2026Article
- PD-L1 in ICI Myocarditis: When the Immune Brake Fails.JACC. CardioOncology · 2026Article
- Myocardial Expression of PD-L1 as a Marker of Poor Prognosis in Immune Checkpoint Inhibitor-Associated Myocarditis.JACC. CardioOncology · 2026Article
- Predictors of Immune-Related Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.Nature reviews. Cancer · 2024Review
- Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.Nature reviews. Cardiology · 2024Review
- Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection.Science advances · 2024Article
- Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.Clinical kidney journal · 2024Review
- Elevated PD-L1 and PECAM-1 as Diagnostic Biomarkers of Acute Rejection in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Circulating immune checkpoints predict heart failure outcomes.ESC heart failure · 2023Article
- Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection.Research square · 2023Article
- Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities.Current oncology reports · 2023Review
- [EJNMMI research · 2023Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Arrush ChoudharyDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.
D Marshall BrinkleyDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-9511-7767
Sepideh BesharatiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD (S.B., Q.Z., R.A.A.).
Wouter C MeijersDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.
James B AtkinsonDepartment of Pathology (J.B.A.), Vanderbilt University Medical Center, Nashville, TN.
Kaushik AmancherlaDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3379-5834
Qingfeng ZhuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD (S.B., Q.Z., R.A.A.).
Shi HuangDepartment of Biostatistics (S.H.), Vanderbilt University Medical Center, Nashville, TN.
Lee S NguyenDepartment of Pharmacology, Sorbonne University, National Institute of Health and Medical Research, CIC-1901, Public Hospitals of Paris, UNICO-GRECO, Paris, France (L.S.N., J.-E.S.).ORCID 0000-0002-6014-6269
Joe-Elie SalemDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-0331-3307
Enrico AmmiratiDe Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy (E.A.).ORCID 0000-0002-1676-5257
JoAnn LindenfeldDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.
Robert A AndersDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD (S.B., Q.Z., R.A.A.).
Javid MoslehiDivision of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-5443-4312
Funding
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3MLong-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3MNHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultB7-H1 AntigenBiomarkersFemaleGraft RejectionHeart FailureHeart TransplantationHumansMaleProgrammed Cell Death 1 ReceptorYoung AdultB7-H1 AntigenBiomarkersCD274 protein, humanProgrammed Cell Death 1 Receptorbiopsygraft rejectionhumansmyocarditisupregulation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.